MET and liver cancer: In HCC, tepotinib has demonstrated preclinical activity in patient-derived primary liver cancer explants, in which sensitivity to the drug was associated with MET overexpression.26 These data, together with the rationale for targeting MET in HCC, led to the design of two Phase 1b/2 trials of tepotinib in patients with aHCC with MET overexpression.